2024
MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy
Fey R, Nichols R, Tran T, Vandenbark A, Kulkarni R. MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy. Cancers 2024, 16: 1773. PMID: 38730725, PMCID: PMC11082995, DOI: 10.3390/cancers16091773.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune-related adverse events developmentResponse to ICB therapyImmune checkpoint blockade therapyImmune checkpoint blockadePredictive biomarkersICB therapyCheckpoint blockade therapySerum MIF levelsBlockade therapyCheckpoint blockadeMIF levelsMalignant melanomaTreatment resistanceSolid tumorsAdverse eventsAutoimmune diseasesContext of cancerPrognostic biomarkerCancer progressionCognate receptor CD74Receptor CD74TherapyCD74Cancer
2020
Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors.
Qin Q, Patel V, Wang B, Mellgard G, Gogerly-Moragoda M, Zhong X, Parikh A, Leiter A, Gallagher E, Galsky M, Oh W, Tsao C. Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors. Journal Of Clinical Oncology 2020, 38: e15160-e15160. DOI: 10.1200/jco.2020.38.15_suppl.e15160.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsMultivariate regression analysisCheckpoint inhibitorsSystemic steroidsSolid tumorsSolid tumors treated with immune checkpoint inhibitorsClinically significant irAEsCombination of immune checkpoint inhibitorsImmune-related adverse events developmentImmune checkpoint inhibitor discontinuationImmune checkpoint inhibitor doseHigher disease control rateDisease control rateFisher's exact testAdverse events developmentIrAE incidenceICI useClinical presentationMedian timeClinical outcomesAntibiotic useAdverse eventsControl rateUnivariate analysisType, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor.
Qin Q, Patel V, Mellgard G, Parikh A, Wang B, Alerasool P, Garcia P, Jaladanki S, Leiter A, Carroll E, Brooks D, Shimol J, Eisenberg E, Gallagher E, Galsky M, Oh W, Tsao C. Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor. Journal Of Clinical Oncology 2020, 38: 480-480. DOI: 10.1200/jco.2020.38.6_suppl.480.Peer-Reviewed Original ResearchImmune related adverse eventsImmune checkpoint inhibitorsRenal cell carcinomaCheckpoint inhibitorsSystemic steroidsUrothelial carcinomaAssociated with immune related adverse eventsCancer treated with immune checkpoint inhibitorsDevelopment of immune related adverse eventsImmune-related adverse events developmentImmune checkpoint inhibitor doseAdvanced urothelial carcinomaPatient baseline characteristicsClinical risk factorsRelated adverse eventsFisher's exact testAdverse events developmentAdvanced UCICI-treatedIrAE developmentCell carcinomaMedian timeTreatment courseBaseline characteristicsClinical outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply